Ionis Pharmaceuticals, Inc.

BMV:IONS * Stock Report

Market Cap: Mex$104.0b

Ionis Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BMV:IONS * Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 May 25BuyMex$9,369,038Michael HaydenIndividual15,000Mex$624.60
31 Jan 25SellMex$889,495C. BennettIndividual1,327Mex$670.31
31 Jan 25SellMex$940,745Richard GearyIndividual1,406Mex$669.09
31 Jan 25SellMex$8,871,478Brett MoniaIndividual13,242Mex$669.95
31 Jan 25SellMex$1,020,082Elizabeth HougenIndividual1,523Mex$669.78
31 Jan 25SellMex$943,291Patrick O'NeilIndividual1,406Mex$670.90
31 Jan 25SellMex$986,555Eugene SchneiderIndividual1,484Mex$664.79
31 Jan 25SellMex$911,853Eric SwayzeIndividual1,367Mex$667.05
23 Dec 24BuyMex$3,655,563Michael HaydenIndividual5,000Mex$731.46

Insider Trading Volume

Insider Buying: IONS * insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of IONS *?
Owner TypeNumber of SharesOwnership Percentage
State or Government71,5930.0423%
Individual Insiders1,338,1220.791%
Institutions167,831,09699.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 87.35% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.8%
FMR LLC
23,613,309Mex$15.4b4.1%0.05%
12.2%
T. Rowe Price Group, Inc.
19,440,567Mex$12.7b8.03%0.06%
10.3%
The Vanguard Group, Inc.
16,383,934Mex$10.7b-0.54%0.01%
7.77%
Capital Research and Management Company
12,361,994Mex$8.1b7.82%0.02%
7.07%
BlackRock, Inc.
11,252,307Mex$7.4b-3.44%0.01%
5.29%
Wellington Management Group LLP
8,416,421Mex$5.5b-2.95%0.05%
4.93%
Bellevue Asset Management AG
7,853,198Mex$5.1b-0.2%3.87%
3.04%
State Street Global Advisors, Inc.
4,845,133Mex$3.2b-10.7%0.01%
2.87%
Deep Track Capital, LP
4,564,207Mex$3.0b136%5.59%
2.19%
Citadel Advisors LLC
3,480,062Mex$2.3b60.7%0.11%
1.87%
Tweedy, Browne Company LLC
2,983,518Mex$1.9b-8.17%1.57%
1.79%
Geode Capital Management, LLC
2,842,954Mex$1.9b5.79%0.01%
1.6%
OrbiMed Advisors LLC
2,540,136Mex$1.7b-9.84%1.37%
1.58%
UBS Asset Management AG
2,510,243Mex$1.6b-1.06%0.01%
1.31%
Two Sigma Advisers, LP
2,092,011Mex$1.4b55.1%0.15%
1.2%
BVF Partners L.P.
1,913,385Mex$1.3b0%2.49%
1.08%
Norges Bank Investment Management
1,714,762Mex$1.1b0%no data
1.06%
Two Sigma Investments, LP
1,685,853Mex$1.1b83%0.12%
1.05%
Macquarie Investment Management Business Trust
1,667,194Mex$1.1b-5.79%0.07%
0.91%
Charles Schwab Investment Management, Inc.
1,443,629Mex$943.5m-2.55%0.01%
0.75%
BNPP Asset Management Holding
1,196,392Mex$781.9m10.7%0.06%
0.69%
TD Asset Management, Inc.
1,100,466Mex$719.2m4.81%0.03%
0.68%
Adage Capital Management, L.P.
1,075,600Mex$703.0m291%0.06%
0.66%
Hudson Bay Capital Management LP
1,049,900Mex$686.2m27.9%0.23%
0.63%
ARK Investment Management LLC
1,000,527Mex$653.9m-2.41%0.26%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 10:22
End of Day Share Price 2025/03/25 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ionis Pharmaceuticals, Inc. is covered by 45 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
James BirchenoughBarclays
Huidong WangBarclays